{"organizations": [], "uuid": "88320b2885988e553d55b51c969013276936c9cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/11", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/08/business-wire-newron-pharmaceuticals-s-p-a-announces-change-in-the-board-of-directors.html", "country": "US", "domain_rank": 767, "title": "Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-08T21:37:00.000+02:00", "replies_count": 0, "uuid": "88320b2885988e553d55b51c969013276936c9cf"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/08/business-wire-newron-pharmaceuticals-s-p-a-announces-change-in-the-board-of-directors.html", "ord_in_thread": 0, "title": "Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors", "locations": [], "entities": {"persons": [{"name": "newron", "sentiment": "none"}, {"name": "don debethizy", "sentiment": "none"}, {"name": "ulrich köstlin", "sentiment": "none"}, {"name": "bo", "sentiment": "none"}, {"name": "bo jesper hansen", "sentiment": "none"}], "locations": [{"name": "milan", "sentiment": "none"}, {"name": "newron", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "newron pharmaceuticals s.p.a.", "sentiment": "negative"}, {"name": "research and development committee", "sentiment": "none"}, {"name": "company's audit & risk committee", "sentiment": "none"}, {"name": "annual shareholders assembly", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Bo Jesper Hansen has informed the Board of Directors of his intention to step down as a Non-Executive Director, effective from this year’s Annual Shareholders Assembly taking place on March 27, 2018.\nUlrich Köstlin, Chairman of Newron, commented: “The Board of Directors and I would like to thank Bo for his dedication and commitment to Newron since he joined the Board in 2013. During his time at Newron, we have seen the approval and launch of our Parkinson’s disease product Xadago® in Europe and the US, and we have made significant progress with our pipeline products Evenamide and sarizotan. He leaves with our sincere thanks and best wishes for the future.”\nBo is member of the Company's Audit & Risk Committee and Chairman of the Research and Development Committee. Non-Executive Director Don deBethizy will take over as Chairman of the Research and Development Committee. Newron is not looking to make any further Non-Executive Director appointments at this time.\nAbout Newron Pharmaceuticals\nNewron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago ® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com\nImportant Notices\nThis document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements, and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange, where the shares of Newron are listed. This announcement is not an offer for sale of securities in the United States, Canada, Australia or Japan or any other jurisdiction where such an offer or solicitation would otherwise be unlawful. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Newron does not intend to register any of its securities in the United States or to conduct a public offering of its securities in the United States. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of this document shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180208006174/en/\nNewron\nStefan Weber, +39 02 6103 46 26\nCEO\npr@newron.com\nor\nUK/Europe\nFTI Consulting\nJulia Phillips or Natalie Garland-Collins, +44 20 3727 1000\nSCnewron@fticonsulting.com\nor\nSwitzerland\nIRF Communications\nMartin Meier-Pfister, +41 43 244 81 40\nmartin.meier-pfister@irfcom.ch\nor\nGermany/Europe\nMC Services\nAnne Hennecke, +49 211 52925222\nanne.hennecke@mc-services.eu\nor\nUSA\nLaVoieHealthScience\nBeth Kurth, +1 617-374-8800, Ext. 106\nbkurth@lavoiehealthscience.com\nSource: Newron Pharmaceuticals S.p.A.", "external_links": ["http://www.businesswire.com/news/home/20180208006174/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.newron.com&esheet=51755928&newsitemid=20180208006174&lan=en-US&anchor=www.newron.com&index=1&md5=4e1710dfcacd30635f56a2e9d23daf38"], "published": "2018-02-08T21:37:00.000+02:00", "crawled": "2018-02-09T01:02:54.010+02:00", "highlightTitle": ""}